Giacobini E
Department of Pharmacology, Southern Illinois University School of Medicine, Springfield.
J Neural Transm Suppl. 1994;43:211-7.
Therapeutic strategies aimed to treat Alzheimer disease (AD) may either produce an attenuation of symptoms or slow down deterioration by attenuating progression of the disease. Presently, cholinesterase inhibitors (ChEI) have shown the most promising therapeutical effects. The best documented clinical efficacy of ChEI are studies of THA (tacrine, tetrahydroaminoacridine). The results of five recent studies in a total of 1,242 patients are reported here. Based on differences from placebo in scoring, a gain of 2-12 (MMSE) or 5-6 (ADAS) months in deterioration can be seen for a THA treatment of 2-3 months duration. This suggests that if treatment with THA will be extended to a longer period, the drug effect may not be only a symptomatic improvement but a slow-down of disease course. A similarity of THA's effect in AD with L-deprenyl effects in Parkinson is suggested.
旨在治疗阿尔茨海默病（AD）的治疗策略可能会减轻症状，或者通过减缓疾病进展来延缓病情恶化。目前，胆碱酯酶抑制剂（ChEI）已显示出最有前景的治疗效果。ChEI最有充分文献记载的临床疗效是对他克林（THA，四氢氨基吖啶）的研究。本文报告了最近五项针对总共1242名患者的研究结果。基于与安慰剂评分的差异，持续2至3个月的THA治疗可使病情恶化时间延长2至12个月（简易精神状态检查表（MMSE）评分）或5至6个月（阿尔茨海默病评定量表（ADAS）评分）。这表明，如果将THA治疗延长至更长时间，药物效果可能不仅是症状改善，还会减缓病程。有人提出THA在AD中的作用与L-司来吉兰在帕金森病中的作用相似。
